Dr. Ines Demoya-Cabrera, MD

Dr. Demoya-Cabrera practices at Centra Specialty Hospital in Lynchburg, Virginia, part of Centra Health.

Dr. Demoya-Cabrera's NPI, 1073877221, was assigned on July 2, 2012. Dr. Demoya-Cabrera holds Virginia license 0101258895.

Dr. Demoya-Cabrera's primary practice is Centra Specialty Hospital, at 3300 Rivermont Avenue, Krise Building, 5th Floor, Lynchburg, VA 24503 in Lynchburg City. The practice phone is (434) 200-1960.

Dr. Demoya-Cabrera's primary practice is Centra Specialty Hospital in Lynchburg, Virginia, part of Centra Health. Dr. Demoya-Cabrera is also affiliated with Centra Lynchburg General Hospital. The medical group on file is Centra Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Demoya-Cabrera practices, 2 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Demoya-Cabrera's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dr. Demoya-Cabrera is board certified in family medicine by the American Board of Family Medicine. Dmand AI has Dr. Demoya-Cabrera's licenses on file in 2 states: Virginia and Pennsylvania.

CMS data shows 1,000 Medicare services from Dr. Demoya-Cabrera across 6 procedure codes in 2024, for 349 Medicare patients. Medicare paid $62,256 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 349 Medicare patients who saw Dr. Demoya-Cabrera in 2024. The largest group is 75 to 84, with 136 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Demoya-Cabrera's median patient age at 75, with 57% women.

In 2024, Dr. Demoya-Cabrera wrote 499 Medicare Part D claims for 222 patients. 90% of them were for generic drugs. CMS names the drug for 236 of them, across 14 drugs with 11 or more claims each, at $1,105 in total drug cost. In 2023, CMS named 130 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Demoya-Cabrera for performance year 2024, reported through an alternative payment model (APM). Dr. Demoya-Cabrera accepts Medicare assignment, so Medicare's approved amount is taken as full payment.